Psomagen (XKRX:950200) Debt-to-Equity : 0.16 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Psomagen Debt-to-Equity?

Psomagen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩1,507 Mil. Psomagen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩3,483 Mil. Psomagen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩32,220 Mil. Psomagen's debt to equity for the quarter that ended in Dec. 2023 was 0.15.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Psomagen's Debt-to-Equity or its related term are showing as below:

XKRX:950200' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.21 Med: 0.15 Max: 0.23
Current: 0.16

During the past 6 years, the highest Debt-to-Equity Ratio of Psomagen was 0.23. The lowest was -5.21. And the median was 0.15.

XKRX:950200's Debt-to-Equity is ranked better than
61.03% of 195 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs XKRX:950200: 0.16

Psomagen Debt-to-Equity Historical Data

The historical data trend for Psomagen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psomagen Debt-to-Equity Chart

Psomagen Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-1.20

0.21

0.23

0.15

0.16

Psomagen Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial													0.15	0.13	0.13	0.15	0.16

Competitive Comparison of Psomagen's Debt-to-Equity

For the Diagnostics & Research subindustry, Psomagen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psomagen's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Psomagen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Psomagen's Debt-to-Equity falls into.

Psomagen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Psomagen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1506.71	+	3482.757)	/	32220.261
	=	0.15

Psomagen's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1506.71	+	3482.757)	/	32220.261
	=	0.15

Psomagen (XKRX:950200) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Psomagen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Psomagen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Psomagen (XKRX:950200) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Psomagen Inc (XKRX:950200) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1330 Piccard Drive, Suite 103, Rockville, MD, USA, 20850

Website

https://www.psomagen.com

Psomagen Inc, formerly Macrogen Corp provides total genomic solutions for both clinical and research purposes. It is mainly focused on end-to-end sequencing services. The company also offers services such as personal DNA tests, clinical sequencing, research sequencing, and others.

Psomagen (XKRX:950200) Headlines

No Headlines